Proteon Therapeutics (PRTO) Raised to “Outperform” at JMP Securities

JMP Securities upgraded shares of Proteon Therapeutics (NASDAQ:PRTO) from a market perform rating to an outperform rating in a research report sent to investors on Monday, MarketBeat.com reports.

Several other research firms also recently commented on PRTO. Zacks Investment Research upgraded Proteon Therapeutics from a sell rating to a hold rating in a report on Saturday, February 9th. HC Wainwright set a $3.00 price objective on Proteon Therapeutics and gave the company a buy rating in a report on Friday, January 25th. Finally, Maxim Group began coverage on Proteon Therapeutics in a report on Tuesday, October 30th. They set a buy rating and a $5.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Proteon Therapeutics currently has a consensus rating of Buy and an average price target of $3.50.

NASDAQ PRTO opened at $2.99 on Monday. The company has a market cap of $56.13 million, a PE ratio of -1.40 and a beta of 0.77. Proteon Therapeutics has a 52 week low of $1.50 and a 52 week high of $3.10.

Institutional investors have recently made changes to their positions in the stock. Comprehensive Portfolio Management LLC bought a new stake in Proteon Therapeutics during the fourth quarter worth $68,000. Vanguard Group Inc grew its holdings in Proteon Therapeutics by 45.9% during the third quarter. Vanguard Group Inc now owns 209,383 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 65,833 shares in the last quarter. Vanguard Group Inc. grew its holdings in Proteon Therapeutics by 45.9% during the third quarter. Vanguard Group Inc. now owns 209,383 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 65,833 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Proteon Therapeutics by 29.8% during the second quarter. Renaissance Technologies LLC now owns 306,481 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 70,381 shares in the last quarter. Finally, New Leaf Venture Partners L.L.C. grew its holdings in Proteon Therapeutics by 1.5% during the fourth quarter. New Leaf Venture Partners L.L.C. now owns 1,523,200 shares of the biopharmaceutical company’s stock worth $3,458,000 after buying an additional 23,200 shares in the last quarter. Institutional investors and hedge funds own 54.37% of the company’s stock.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.

Read More: Stop Order Uses For Individual Investors

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit